Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda with Radiation and Temozolomide in Newly Diagnosed Glioblastoma
NCT02530502Phase 1Terminated
- Sponsor
- Northwestern University
- Start
- Sep 2015
- Primary completion
- May 2016
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in glioblastoma (GBM), sponsored by Northwestern University. Primary endpoint: Dose-Limiting Toxicity at 9 weeks. Started Sep 2015; status: terminated.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02530502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530502.